This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...